Your browser doesn't support javascript.
SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies
S Momsen Reincke; Meng Yuan; Hans-Christian Kornau; Victor M Corman; Scott van Hoof; Elisa Sánchez-Sendin; Melanie Ramberger; Wenli Yu; Yuanzi Hua; Henry Tien; Marie Luisa Schmidt; Tatjana Schwarz; Lara Maria Jeworowski; Sarah E Brandl; Helle Foverskov Rasmussen; Marie A Homeyer; Laura Stöffler; Martin Barner; Désirée Kunkel; Shufan Huo; Johannes Horler; Niels von Wardenburg; Inge Kroidl; Tabea M Eser; Andreas Wieser; Christof Geldmacher; Michael Hoelscher; Hannes Gänzer; Günter Weiss; Dietmar Schmitz; Christian Drosten; Harald Prüss; Ian A Wilson; Jakob Kreye.
  • S Momsen Reincke; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology and Experimental Ne
  • Meng Yuan; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
  • Hans-Christian Kornau; Neuroscience Research Center (NWFZ), Cluster NeuroCure, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität B
  • Victor M Corman; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Virology, Berlin, Germany and
  • Scott van Hoof; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology and Experimental Ne
  • Elisa Sánchez-Sendin; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology and Experimental Ne
  • Melanie Ramberger; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology and Experimental Ne
  • Wenli Yu; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
  • Yuanzi Hua; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
  • Henry Tien; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
  • Marie Luisa Schmidt; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Virology, Berlin, Germany and
  • Tatjana Schwarz; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Virology, Berlin, Germany and
  • Lara Maria Jeworowski; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Virology, Berlin, Germany and
  • Sarah E Brandl; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology and Experimental Ne
  • Helle Foverskov Rasmussen; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology and Experimental Ne
  • Marie A Homeyer; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology and Experimental Ne
  • Laura Stöffler; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology and Experimental Ne
  • Martin Barner; Helmholtz Innovation Lab BaoBab (Brain antibody-omics and B-cell Lab), Berlin, Germany
  • Désirée Kunkel; Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Flow & Mass Cytometry Core Facility, Berlin, Germany
  • Shufan Huo; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology and Experimental Ne
  • Johannes Horler; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology and Experimental Ne
  • Niels von Wardenburg; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology and Experimental Ne
  • Inge Kroidl; Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Germany
  • Tabea M Eser; Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Germany
  • Andreas Wieser; Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Germany
  • Christof Geldmacher; Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Germany
  • Michael Hoelscher; Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Germany
  • Hannes Gänzer; Department of Internal Medicine, BKH Schwaz, Schwaz, Austria
  • Günter Weiss; Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria
  • Dietmar Schmitz; Neuroscience Research Center (NWFZ), Cluster NeuroCure, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität B
  • Christian Drosten; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Virology, Berlin, Germany and
  • Harald Prüss; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Virology, Berlin, Germany and
  • Ian A Wilson; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
  • Jakob Kreye; Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology and Experimental Ne
Preprint in English | bioRxiv | ID: ppbiorxiv-462420
Journal article
A scientific journal published article is available and is probably based on this preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See journal article
ABSTRACT
SARS-CoV-2 Beta variant of concern (VOC) resists neutralization by major classes of antibodies from non-VOC COVID-19 patients and vaccinated individuals. Here, serum of Beta variant infected patients revealed reduced cross-neutralization of non-VOC virus. From these patients, we isolated Beta-specific and cross-reactive receptor-binding domain (RBD) antibodies. The Beta-specificity results from recruitment of novel VOC-specific clonotypes and accommodation of VOC-defining amino acids into a major non-VOC antibody class that is normally sensitive to these mutations. The Beta-elicited cross-reactive antibodies share genetic and structural features with non-VOC-elicited antibodies, including a public VH1-58 clonotype targeting the RBD ridge independent of VOC mutations. These findings advance our understanding of the antibody response to SARS-CoV-2 shaped by antigenic drift with implications for design of next-generation vaccines and therapeutics. One sentence summarySARS-CoV-2 Beta variant elicits lineage-specific antibodies and antibodies with neutralizing breadth against wild-type virus and VOCs.
Full text: Available Collection: Preprints Database: bioRxiv Type of study: Randomized controlled trials Topics: Vaccines / Variants Language: English Year: 2021 Document Type: Preprint

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Collection: Preprints Database: bioRxiv Type of study: Randomized controlled trials Topics: Vaccines / Variants Language: English Year: 2021 Document Type: Preprint